Steven Hildemann

Summary

Affiliation: Essex pharma
Country: Germany

Publications

  1. ncbi Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice
    Steven K Hildemann
    Essex pharma, Medical Department, Munich, Germany
    Curr Med Res Opin 23:713-9. 2007
  2. ncbi Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care
    Steven Hildemann
    Medical Department, Essex pharma, Munich, Germany
    Curr Med Res Opin 24:1659-68. 2008
  3. ncbi Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice
    Steven K Hildemann
    Essex pharma, Medical Department, Munich, Germany
    Curr Med Res Opin 24:2777-84. 2008
  4. ncbi Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1
    S K Hildemann
    Essex Pharma GmbH, Munich, Germany
    Hamostaseologie 29:349-55. 2009

Detail Information

Publications4

  1. ncbi Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice
    Steven K Hildemann
    Essex pharma, Medical Department, Munich, Germany
    Curr Med Res Opin 23:713-9. 2007
    ..6 mmol/L) low density cholesterol (LDL-C) cholesterol threshold in the primary care setting...
  2. ncbi Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care
    Steven Hildemann
    Medical Department, Essex pharma, Munich, Germany
    Curr Med Res Opin 24:1659-68. 2008
    ....
  3. ncbi Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice
    Steven K Hildemann
    Essex pharma, Medical Department, Munich, Germany
    Curr Med Res Opin 24:2777-84. 2008
    ..We aimed to describe the usage pattern, effectiveness and tolerability of long-term treatment with lipid-lowering agents, with particular focus on an oral combination of simvastatin (SIM 10, 20, 40 or 80 mg) plus ezetimibe (EZ 10 mg)...
  4. ncbi Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1
    S K Hildemann
    Essex Pharma GmbH, Munich, Germany
    Hamostaseologie 29:349-55. 2009
    ....